Scynexis Prepares For NDA Filing With Second Phase III Success In VVC

 
• By Joseph Haas
Detailed view of a sprinter getting ready to start. Selective focus.
With two successful Phase III studies, Scynexis is ready to file novel antifungal for approval

More from Clinical Trials

More from R&D